Department of Medical Biology, Faculty of Medicine, Ege University, Bornova/Izmir, Turkey.
Med Oncol. 2024 Nov 25;42(1):14. doi: 10.1007/s12032-024-02562-8.
Breast cancer is a major health problem, accounting for one third of all cancers in women. There is no definitive treatment for breast cancer and its incidence is increasing worldwide every year. Furthermore, breast cancer stem cells cause resistance to radiation and chemotherapy. Telomerase is an enzyme that protects telomeres and is activated in 90% of cancer cells, and telomerase activation is a hallmark of cancer. In this review, we examine telomerase activation in breast cancer and breast cancer stem cells and the therapeutic effects of telomerase inhibition in these cells. In this review, we aim to highlight the importance and impact of telomerase inhibition in the treatment of breast cancer and the lack of studies specifically in breast cancer stem cells.
乳腺癌是一个主要的健康问题，占所有女性癌症的三分之一。目前还没有针对乳腺癌的明确治疗方法，其发病率每年在全球范围内都在增加。此外，乳腺癌干细胞导致对放疗和化疗的耐药性。端粒酶是一种保护端粒的酶，90%的癌细胞中都有端粒酶的激活，而端粒酶的激活是癌症的一个标志。在这篇综述中，我们研究了端粒酶在乳腺癌和乳腺癌干细胞中的激活以及端粒酶抑制在这些细胞中的治疗效果。在这篇综述中，我们旨在强调端粒酶抑制在乳腺癌治疗中的重要性和影响，以及在乳腺癌干细胞中缺乏具体研究的情况。
